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Sex differences in anthracycline-induced cardiotoxicity: the benefits of estrogens 
Christian Cadeddu Dessalvi1, Alessia Pepe2, Claudia Penna3, Alessia Gimelli4, Rosalinda Madonna5 , 
Donato Mele6, Ines Monte7, Giuseppina Novo8, Cinzia Nugara8, Concetta Zito9, Javid J Moslehi1 0 , 
Rudolf A de Boer11, Alexander R Lyon12, Carlo G Tocchetti13,14, Giuseppe Mercuro1  
Anthracyclines are the cornerstone for many oncologic treatments, but their cardiotoxicity has been recognized 
for several decades. Female subjects, especially before puberty and adolescence, or after menopause, seem to 
be more at increased risk, with the prognostic 16 impact of this sex issue being less consistent compared to 
other cardiovascular risk factors. Several studies imply that sex differences could depend on the lack of the 
protective effect of sex hormones against the anthracycline-initiated damage in cardiac cells, or on 18 
differential mitochondria-related oxidative gene expression. This is also reflected by the results obtained with 
different diagnostic methods, such as cardiovascular biomarkers and imaging techniques (echocardiography, 
magnetic resonance, and nuclear medicine) in the diagnosis and monitoring of cardiotoxicity, confirming that 
sex differences exist. The same is true about protective strategies from anthracycline cardiotoxicity. Indeed, 
first studied to withstand oxidative damage in response to ischemia/reperfusion (I/R) injury, cardioprotection 
has different outcomes in men and women. A number of studies assessed the differences in I/R response 
between male and female hearts, with oxidative stress and apoptosis being shared mechanisms between the 
I/R and anthracyclines heart damage. Sex hormones can modulate these mechanisms, thus confirming their 
importance in the pathophysiology in cardioprotection not only  from the ischemia/reperfusion damage, but 
also from anthracyclines, fueling further cardio-oncologic research on the topic. 
Keywords  Anthracycline cardiotoxicity . Gender differences . Pathophysiology, monitoring, and protection 
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Anthracyclines are first-line therapies for the treatment of many malignancies; unfortunate ly, 
their efficacy is limited by cardiotoxicity (CTX), which is dose-dependent. Recent clinical guidelines 
on cardiotoxicity from anticancer drugs highlight that identification of subjects at a higher risk is a 
fundamental step in successful screening and pre-emptive treatment [1-3]. Many factors includ ing 
cumulative dose, body mass index >30kg/m2 (especially for anti-HER2 compounds) [4], age (elderly 
and pediatric population treated with anthracyclines) [5-8], concomitant or previous radiation 
therapy, previous cardiotoxic anticancer therapies, pre-existing cardiovascular disease (CVD) [9], 
demographic and other CV risk factors, as well as common lifestyle and genetic risk factors may 
predispose patients to CTX, already  at mild to intermediate doses of anthracyclines [1,2,5, 10-12].  
In particular, the association between obesity (BMI ≥ 30 kg/m2) and high risk of heart failure 
has been well established. In addition, previous studies demonstrated that obesity was an important 
prognostic factor that affected both overall survival and disease-free survival in patients with breast 
cancer [13]. The mechanisms by which obesity could negatively influence cardiotoxicity are affected 
by numerous confounding factors. Obesity may increase the expression of pro-inflammatory 
adipokines and downregulate the anti-inflammatory adipokines, which could result in an adipokine 
imbalance and maintain a chronic inflammatory state to promote the development of cardiovascular 
diseases. Second, patients with obesity are more sensitive to the cardiotoxic effects of anthracyclines ; 
an animal model of rats with a high lipid diet showed similar results. Finally, obesity is significantly 
associated with activation of neurohormones, increased oxidative stress, increased hemodynamic 
load, and remodeling of the left ventricle[14] .  
In addition, ErbB2 (or HER2) seems to be a modulator of oxidative stress, with anti-ErbB2 
drugs being able to block protective mechanisms triggered by ErbB2, thus enhancing the oxidative 
damage induced by anthracyclines. The interactions between anthracyclines and trastuzumab have 
been extensively studied. Importantly, in breast cancer, coadministration of trastuzumab with ANTs 
in the first trials increased the latter’s toxicity and is now avoided [15–18]. 
Also, protocols with elevated anthracyclines dosages (cumulative doses higher than 350 
mg/m2) are being seldom used, due to the increased risk of cardiotoxicity.  
It is important to assess the best protocols for early identification of these high-risk patients 
and for follow-up during cancer therapies, in order to be able to obtain optimal protection from cardiac 
damage [19]. This paper describes the importance of sex differences in pathophysiology of 
anthracycline cardiotoxicity, in the assessment and monitoring imaging techniques of this 
cardiomyopathy, and in the protection from cardiac damage induced by this chemotherapeutic. In 
terms of protection, here we focus on the role of estrogens, acknowledging that in the CECCY trial, 
no difference was seen between carvedilol and placebo in both subgroups pre- and post-menopause 
[20], while in the MANTICORE [ 21],there is no mention of menopausal status. 
 
SEX DIFFERENCES OF ANTHRACYCLINE-INDUCED CARDIOTOXICITY 
Anthracyclines can lead to cell dysfunction and death by interfering with mitochondria l 
function, bioenergetics, signaling pathways and redox balance [5,22]. Most of these targets are known 
to exhibit sexual dimorphism, like “redox features” of cells (i.e., different aspects of redox-associated 
molecules and enzymes in regard to gender differences in terms of the intracellular production and 
biochemical activity of reactive species) and expression of mitochondria-related genes at different 
ages [23,24] In addition to pharmacodynamics, sex-specific differences in pharmacokinet ics 
(absorption, distribution, excretion) may have important clinical consequences, influencing drug side 
effects. Regarding doxorubicin and its main metabolite doxorubicinol, important intra- and inter-
patient variations in pharmacokinetic parameters have been demonstrated [25]. Several authors 
showed that men have a significantly higher doxorubicin clearance than women [26]. This was 
supported by the finding of a higher proportion of doxoubicinol detected in the men, which could be 
related to a greater aldoketoreductase activity. [27]. Moreover, doxorubicin and doxorubicinol might 
accumulate following a reduced expression of p-glycoprotein in females, leading to higher ate of 
cardiotoxicity [ 28]. 
A comparable sex-based difference has been reported for the pharmacokinetics of epirubic in 
[27]. Therefore, sex-specific characteristics in anthracycline- induced cardiotoxicity can be potentially 
expected based on both the pharmacodynamic and pharmacokinetic profile.  
Experimental data point toward better resistance of females regarding CTX with involvement 
of mitochondria and less oxidative stress, in fact very few studies have been conducted in humans, 
with female patients in clinical studies rather appearing to be more susceptible to doxorubicin- induced 
CTX [1,29,30]. This apparent paradox may be explained because both age and the menopausal state 
of female patients seem to be the two most important determinants of the sex-specific differences 
observed in the clinical setting, with higher susceptibility of prepuberal girls and post-menopausa l 
women (Figure 1). Studies in young children receiving anticancer drugs for hematologica l 
malignancies [29,31] suggest that prepuberal girls are more susceptible to develop early or late 
cardiac toxicity than boys of the same age. These data are consistent with absence of female hormones 
at this age. Unfortunately, no survey has been conducted to specifically assess sex differences in the 
occurrence of anthracycline cardiotoxicity in adults. Studying the cardiac status of long- term 
survivors (at least 5 years after therapy) and estimating the features of subclinical cardiotoxic ity 
induced after conventional treatment of lymphoma with doxorubicin, some authors found that male 
sex was related, together with other factors, to the development of subclinical cardiotoxicity [32]. In 
cohort studies of cancer survivors, the predicted 10-year cumulative incidence of congestive heart 
failure for males without or with preexisting cardiac disease is higher than in females [33,34].  
In addition, the majority of breast cancer patients are post-menopausal [35], supporting the 
hypothesis of protection conferred by female sex hormones against doxorubicin cardiotoxic ity. 
Interestingly, doxorubicin itself seems to be likely to cause premature ovarian failure, with a sharp 
decline in female sex hormones [36]. 
In studies concerning hematological malignancies, both sexes were treated risk factor for 
adverse cardiac events and the authors attributed  this to a higher baseline cardiac disease in males 
[33]. In addition, data with hematological malignancies in postmenopausal women suggest that 
similar baseline cardiovascular health in elderly men and women leads to similar susceptibility to 
anthracycline- induced cardiotoxicity [37]. Oxidative stress is well known to play a major role in 
anthracycline- induced cardiotoxicity. Reactive Oxygen Species (ROS) include several oxygen 
radicals such as Superoxide (O−2•) and hydroxyl radicals (OH•), and non-radicals molecules, e.g. 
hydrogen peroxide (H2O2) and singlet oxygen (1O2). Also the Reactive Nitrogen Species (RNS) 
comprise radicals such as Nitric Oxide (NO•) and Nitric Dioxide (NO2•), and non-radicals, e.g. 
nitrous acid (HNO2) and dinitrogen tetroxide (N2O4)  
Overproduction of ROS and RNS induced by  anthracyclines determines redox stress, which induces 
cardiac injury [5], including DNA damage and lipid peroxidation, leading to membrane injury and/or 
apoptosis and alterations  of the enzymatic activity of the mitochondrial redox system. Among altered 
enzymes are those of the respiratory complexes, the enzymes of Krebs cycle, oxidative 
phosphorylation, and β-oxidation and nitric oxide synthases (NOSs) [ 18]. While cross-talk in breast 
cancer cell lines between estrogen receptors and ROS/Notch/Wnt pathways may play an important 
role in regulating cell death, differentiation, and angiogenesis [38, 39], a complex inter-relationship 
between estrogen receptors and enzyme activity involved in redox mechanisms may sustain different 
oxidative stress that mediates cardiotoxicity in a gender-specific manner. In support of this 
hypothesis, the work of Gonzalez and colleagues [ 40] demonstrates that adult tumor-bearing male 
SH rats are more cardiosensitive to doxorubicin treatment than female or hormone-deficient animals. 
These results suggest that repro181ductive hormones regulate doxorubicin- induced 182cardiotoxic ity 
and the selective cytotoxic mechanism likely 183functions through the greater activation of oxidative 
stress 184and apoptosis in male SH rats [40]. 
 
SEX DIFFERENCES IN ASSESSMENT AND MONITORING OF ANTHRACYCLINES 
TOXICITY 
Beside the pathophysiology of anthracycline-cardiotoxicity, sex differences may also prompt 
differential assessment and monitoring of patients who are treated with these drugs. 
Transthoracic echocardiography (TTE) is the most useful tool to monitor cardiac function in 
patients undergoing chemotherapy because of its safety, availability and low cost [41]; nonetheless, 
there are some sex-related differences that should be considered during a TTE evaluation of patients 
with suspected cardiotoxicity. Indeed, pathophysiological and epidemiological features, specific of 
female sex, often imply higher heart rate, smaller ventricles with seemingly higher contractility, 
supraventricular arrhythmias, and higher prevalence of HFpEF [42,43.]. Although LVEF is a gross 
and poorly sensitive parameter to evaluate cardiotoxicity, it is still the most used parameter for follow-
up of oncologic patients [1,44]. The last TTE recommendations indicate as normal a LVEF (by 2D-
modified Simpson’s rule) >52% for men and 54% for women [45]. Cardiotoxicity has been defined 
as a decrease in LVEF of >10% to a value <53% [44] (or <50% independent from sex) [1]. However, 
LVEF is poorly sensitive for the detection of small changes in LV contractility, particularly if these 
are limited to few segments and in hypertrophic, small ventricles, as often occurs in women. 
[46,47].Thus, it should be combined with wall motion score index (WMSI) calculation which enables 
the identification of early regional damage very common in women treated with trastuzumab 
[44](Figure 2). A 5-unit fall of contractile reserve at low-dose dobutamine stress echocardiography 
in women with breast cancer seems to be able to predict subsequent LVEF reduction <50% [48]. 
Importantly, WMSI has been applied in previous clinical studies. A work from the early son 
hematological malignancies suggested that the 16-segment evaluationof LV function at rest by WMSI 
might be superior to global 2D measurement of EF. Moreover, gradual worsening of WMSI during 
anthracyclines paralleled the decline of radionuclide EF [49]. Also, autopsy studies have shown that 
the cardiac injury caused by anthracyclines is patchy, and at times is limited to one or more ventric le 
walls [50]. Therefore, segmental abnormalities can be detected before any global systolic LV 
dysfunction is apparent. More recently, in childhood cancer survivors (CCS) treated with 
anthracyclines, platinum, and/or radiotherapy between 1976 and 1999, at 18 years post-treatment, 
there was an increased prevalence of abnormal WMSI compared to controls, and NT-proBNP was 
associated to increased WMSI [51]. In addition, CCS with persistent LV regional wall motion 
abnormalities (WMA) show reduced LV myocardial performance, evaluated through 3D speckle 
tracking echocardiography, compared with those without WMA, despite a preserved LVEF. Multip le 
linear regression analysis identified global radial strain as a significant determinant of the existence 
of WMA in these patients [52]. 9Indeed, global systolic longitudinal strain (GLS) was recognized to 
accurately predict a subsequent decrease in LVEF in several studies on women treated with 
anthracyclines with or without additional agents [53]. A relative percentage reduction of GLS of 
>15% from baseline is considered abnormal and a marker of early LV subclinical dysfunction in the 
last position statement [ 1],based on the results of a study in women with breast cancer treated with 
trastuzumab, with or without anthracyclines. In this context, it is important to refer to 
248meanvaluesforGLSaccordingtosexandage, because values of GLS are slightly higher in women 
than in men [ 54]. Kocabay and colleagues reported a mean normal GLS of 20.7±2 for men and 
22.1±1.8 for women [ 55].These values are almost identical to the ones reported by the Japanese 
Ultrasound Speckle Tracking of the Left Ventricle (JUSTICE) study for the same vendor, showing 
an effect of gender on GLS values [ 56]. Interestingly, in early 2019, Barros and colleagues analyzed 
prospectively the role of LV WMSI among echocardiographic parameters in the prediction of 
development of cardiotoxicity in breast cancer patients undergoing chemotherapy. In the multivar ia te 
analysis using the logistic regression model, LVWMA, LV systolic dimension increase and GLS 
reduction were strongly associated with cardiotoxicity and could be use full in risk stratification of 
these patients [ 57]. In summary, during cardiac toxicity monitoring it is very helpful to refer to 
current recommendations on the cardiac chamber normal values [ 45]. It is also strongly 
recommended not only to use TTE parameters of global function such as EF, volumes, and GLS, but 
also to refine the analysis through the regional function assessment (WMSI and bull ’s eye map of 
longitudinal strain),in both baseline patient ’sex amination and during follow-up [ 58]. As for the 
other cardiac evaluations (valves, atria, right ventricle, pericardium), no particular gender-related 
difference was found in TTE studies on cardiotoxicity diagnosis and monitoring.  
Cardiovascular magnetic Resonance (CMR) is an ionizing radiation-free imaging method 
accepted as the gold standard for quantifying biventricular parameters. It is well known that 
biventricular function parameters are strongly correlated to gender and age [59]. Thus, in clinica l 
practice it is strongly recommended to apply cut off values according to gender and normalized to 
body surface area (BSA) for the volumes and the mass in order to accurately detect cardiotoxic ity 
related to anthracyclines. Many studies showed a significant decrease in LVEF due to chemotherapy 
treatment. In adult patients LVEF changes seem to be not affected by sex [60]. One study involving 
62 long-term survivors of childhood cancer showed a trend toward a male predominance among those 
with an abnormal LVEF (29% vs 9%; P=0.053) and RVEF (39% vs 18%; P=0.057) [61]. Post-
treatment biventricular volumes and LV mass were significantly higher in males, but these parameters 
were not normalized to BSA [62]. .Moreover, these  results can be a consequence of the different 
morphology of  male and female hearts, due to different adrenergic and hormonal states [63], body 
weight, height, different muscular mass, and body conformation. Importantly, sex differences  can be 
observed in hemodynamics only in patients with normal LV function, but not with HF: Mitoff and 
colleagues  speculated that the intrinsic or extrinsic factors responsible  for sex differences in patients 
with normal cardiac function  may be masked by the HF disease state or its treatment [64]. 
CMR provides an accurate and reliable evaluation of myocardial deformation by tagging 
techniques and few studies  have demonstrated a significant decrease in longitudinal and 
circumferential deformation in chemotherapy-treated patients  compared with controls [65]. In 46 
asymptomatic post chemotherapy pediatric patients average circumferential and longitudinal strain 
magnitude was lower among male subjects, but this finding was due to the fact that gender affects 
normal values [62] and this issue was not taken in account in the study.  
In the evaluation of anthracycline-induced CTX, CMR has the unique feature of providing 
information on tissue characterization. In fact, chemotherapeutic agents can cause oedema and 
hyperaemia, and even cellular necrosis and subsequent fibrosis. No study has evaluated if the 
prevalence of oedema was different between males and females. Macroscopic fibrosis can be detected 
by means of the late gadolinium enhancement (LGE) technique and its presence is a strong 
prognosticator in all cardiomyopathies [44]. Diffuse myocardial fibrosis can be detected by T1 
mapping with the evaluation of the extracellular volume (ECV). Toro-Salazar et al. found that T1 
values after contrast administration were significantly lower in 46 long-term survivors in comparison 
with volunteers, revealing mild diffuse fibrosis [62]. In this study, as well as in a study by Tham et al 
[66], treated females showed higher mean ECV and lower postcontrast myocardial T1 values 
compared to males. Similar trends were detected in studies involving healthy subjects, and thus may 
reflect general sex differences.  
In recent years, several biomarkers have been tested in the context of anticancer anthracycline-
induced cardiotoxicity [67]. However, their use is severely hampered by important sex-specific 
differences [68]. Specifically, high sensitivity-troponin levels are about 50% lower in women than in 
men, while NT-proBNP levels are 50% higher [69]. Cardinale et al observed a greater prevalence of 
women in a group of patients with L-TnI levels > 0.08 ng/mL with a further increase; they also noted 
that in breast cancer TnI was most commonly positive [70]. However, another study showed that 
gender had no influence on the occurrence of cTnT positivity [71]. 
Use of BNP or N-terminal pro-B-type natriuretic peptide (NT-proBNP) to detect subclinica l 
CTX is under investigation and results of published studies are controversial [72-74]. Also, increases 
of gal3 were found to be not predictive of anthracycline- induced CTX as defined by echo-derived 
LVEF reduction, and no data are available about differences between the sexes [75]. 
 
SEX DIFFERENCES IN CARDIOPROTECTION 
Acknowledgment of sex differences in the mechanisms and clinical manifestations of 
anthracyclines cardiotoxicity may help elucidate cardioprotective approaches and develop therapeutic 
strategies. The concept of cardioprotection was introduced in the 1960s with pharmacological and 
reperfusion interventions, following an ischemic damage, and has evolved to include several 
strategies that may save the functionality and vitality of cardiac cells jeopardized by 
ischemia/reperfusion (I/R) or toxic insult [76]. 
Despite the fact that experimental and pre-clinical studies clearly demonstrate 
cardioprotective benefits with conditioning strategies, their translation into clinical therapy has been 
disappointing [77]. This is due to several reasons, including the complexity of the cellular mechanism 
of cardioprotection. Furthermore, additional confounding factors such as age, comorbidit ies , 
comedications and gender may affect the injury, as well as the endogenous cardioprotective aspects 
triggered by conditioning procedures [78,79]. Cardioprotective strategies that have been first adopted 
against the oxidative damage that characterizes the ischemia/reperfusion injury, have different 
outcomes according to the sex analyzed.  Estrogens may play a role in modulating protection from 
anthracyclines cardiotoxicity, too, but their roles in cardioprotection deserve further studies. 
A number of studies analyzed the differences in I/R response between male and female hearts, 
and there are numerous epidemiological data reporting that premenopausal females have a reduced 
risk for cardiovascular disease [80–86]. In the majority of studies, estrogens are considered 
380responsible for the better tolerance to I/R by female hearts [ 87],as we have already described in 
a previous section about estrogens protecting from cardiac injury from anthracyclines. Endogenous 
estrogens may affect with tonic and phasic effects cardiovascular homeostasis in premenopausa l 
females and may interfere with the development of several cardiovascular diseases, includ ing 
coronary artery disease (Fig. 3). Acting on three receptors (ERs), namely ER α, ER β, and 388GPER, 
estrogens exert transcriptional regulation. Moreover, GPER is implicated in rapid, phasic signaling 
via RISK pathway. Indeed, estrogen receptor activation induces the activation of PI3-kinase 
(PI3K)/Akt signaling converging on nitric oxide (NO) synthases (NOS) [87]. Nitric oxide plays a 
central role in mechanisms of cardioprotection and may be a  key factor in gender differences. 
Estrogen-induced NO production favors S-nitrosylation (SNO) and closure of L-type Ca2+channels 
so that cytosolic and mitochondrial calcium  overload during ischemia and early reperfusion is 
reduced  [88]. Mechanisms related to the control of Ca2+ homeostasis  and mitochondrial function 
may be important in determining  gender differences not only in response to I/R, but also to 
anthracycline challenge. The importance and gender differences of NO pathway in regulating the 
expression of genes relateddirectlyandindirectlytocardiomyocyteCa2+ handling  have been recently 
confirmed by Bienvenu and coworkers  [89]. 
Recently, Murphy and colleagues have demonstrated a characterization of the sex-dependent 
cardiac SNO proteome [90]. Interestingly, higher level of SNO in membrane fractions derived from 
female hearts with respect the level found in male hearts have been described, [91]. The same group 
also showed that female hearts display higher cardiac eNOS expression and that the estrogen-
dependent NOS activation/phosphorylation induces NO production, which in turn enhances SNO 
protein levels and consequently a cardioprotective phenotype occurs. Conversely, in male hearts, the 
expression of eNOS is reduced, with minor production of nitric oxide derivative and SNO protein 
levels [90]. The cardioprotective effects of SNO proteins are demonstrated in several reports [92]. In 
female hearts, it has been also demonstrated that enhanced S-nitrosoglutathione reductase (GSNOR) 
activity may play a role in the cardioprotective pathway by limiting protein SNO from accumulat ing 
to levels that are at risk to trigger deleterious nitrosative stress [90]. 
As we have already described in a previous section, estrogens are very important not only in 
modulating the ischemia/reperfusion damage, but also in protecting from cardiac injury from 
anthracyclines. Indeed, oxidative stress and apoptosis are shared mechanisms between the I/R and 
anthracyclines heart damage. Hence, anthracyclines are better tolerated in female adult 
cardiomyocytes [93] in experimental models [40]. Intriguingly, regardless of any therapy, cancer 
itself can induce cardiac atrophy and autophagy in a sexually dimorphic way, with estrogens 
conferring protection against cancer-induced cardiac atrophy and body weight loss by signaling 
through its receptor [94]. 
Other mechanisms of doxorubicin cardiotoxicity are related to mitochondrial dysfunction and 
down-regulation of energy metabolism signaling pathways [5,22]. In male rats, doxorubicin treatment 
resulted in important alterations in mitochondrial function, which appeared unaffected or remarkably 
preserved in treated females [95]. Moreover, mitochondrial dysfunction and energy metabolism 
signaling pathways seem associated with early cardiotoxicity in males but not in females [95], with 
doxorubicin altering mitochondria more severely in males, as evidenced by a downregulation of gene 
expression of mitochondrial biogenesis, mitochondrial function and mitochondrial dynamic, 
decreased mitochondrial respiration, and mitochondrial DNA content. Also, a sex-specific impact of 
doxorubicin on the heart phospholipidome, especially on cardiolipin, an essential mitochondrial lipid, 
has also been shown [96]. 
We have shown recently that estrogens may influence the cardiotoxicity of antineoplast ic 
drugs, with the activation of GPER mitigating the cardiotoxic effects of Doxorubicin (Dox), thus 
suggesting GPER as an interesting pharmacological target to limit the detrimental myocardial effects 
of Dox treatment [97]. Some animal studies show that females develop less cardiomyopathy and 
nephropathy than males after chronic administration of anthracyclines [98,99], but such protection is 
abrogated after ovariectomy [99]. On the other hand, 17-β -estradiol confers protection against cardiac 
injury in ovariectomized rats treated with Dox [100]. These observations seem to indicate a protective 
role of female hormones. Intriguingly, it has been also observed that testosterone is able to protect 
from ANT-induced damage in cardiac myocytes in vitro [101]. 
 
CONCLUSIONS 
The studies we reviewed suggest there are sex differences in  the triggering of specific 
cardioprotective signaling pathways  in response to cardiac injury. Tonic and phasic estrogen actions 
on specific receptors may explain many of gender differences in I/R injury, in cardiotoxicity from 
anthracyclines, in post-ischemic systolic recovery and in conditioning protection. The intricate inter-
relationship between estrogen receptors, NOS activity, and other related or not related mechanisms, 
acute and chronic conditions, and their roles in cardioprotection deserve further studies, with large 
clinical  studies and more complex preclinical models that take into  account sex differences, in order 
to get more insight into clinical applicability of novel approaches for diagnosis and protection from 
anthracycline cardiotoxicity. Considering the impact that confounding factors including gender 
differences  have on the triggering cardiac injury as well as on the effects  of cardioprotective 
therapies, extrapolation from animal findings to clinical relevance in humans should be made 
cautiously [102],since estrogens may play a role of in increased risk of malignancy, with the majority 
of post-menopausal women  having ER + breast cancer. 
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Sexual dimorphism of anthracycline cardiotoxicity 
 
Figure 2: 
Bull's eye map of LV longitudinal strain showing early reduction of  
myocardial deformation at the basal LV segments (especially of the septum and  
anterior wall) in a woman treated with anticancer therapies. 
 
Figure 3: 
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